Navigation Links
Alseres Pharmaceuticals Concludes Enrollment in the Cethrin(R) Phase I/IIa Clinical Trial in Acute Spinal Cord Injury
Date:1/7/2008

rietary protein that inactivates the action of Rho, a key enzyme that prevents axon regeneration and recovery after SCI. It has been granted Orphan Drug Status in the U.S. In February 2005, enrollment began in an open-label, non-placebo-controlled, dose-escalating Phase I/IIa trial in subjects with acute SCI at sites in the United States and Canada. The trial assessed 5 dose levels of Cethrin from 0.3 mg to 9 mg in both thoracic and cervical injuries.

The trial design includes a number of post-treatment evaluations of the subjects for safety and efficacy for up to one year after treatment. The efficacy measurements assess changes in subjects' sensory and motor functions, as well as overall recovery as measured by the American Spinal Injury Association, or ASIA, Impairment Scale. The ASIA Impairment Scale is used to score subjects within five categories from A to E, with A being complete impairment with no sensory or motor function below the site of injury and E being normal. Grades B through E designate increasing levels of motor and sensory function. The subjects in the Cethrin Phase I/IIa trial suffered a complete thoracic or cervical SCI and were thus classified as an A on the ASIA Impairment Scale at the time of enrollment in the trial.

The 6-month interim data on 37 of these subjects treated with doses of up to 6 mg indicate that 27% of the Cethrin treated subjects improved from ASIA A to ASIA B or better. This is more than 400% greater than the conversion rate seen with the standard of care in a similarly designed study reported by Burns and colleagues in the Journal of Neurotrauma. When subjects with cervical injuries who were treated with Cethrin were analyzed separately, about 46% of the subjects exhibited a conversion rate from ASIA A to ASIA B or better. Moreover, about 18% of subjects overall and 38% of subjects with cervical injuries improved to ASIA C or better over the six months the hallmark of which is recovery of some motor function.
'/>"/>

SOURCE Alseres Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Alseres Pharmaceuticals Initiates the ALTROPANE(R) POET-2 Phase III Clinical Trial Program
2. Alseres Pharmaceuticals Announces Expansion of the Cethrin(R) Acute Spinal Cord Injury (SCI) Phase I/IIA Clinical Trial
3. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
4. QuatRx Pharmaceuticals Announces Positive Phase 3 Results for Study of Ophena(TM) (ospemifene) to Treat Postmenopausal Vaginal Syndrome
5. Solvay Pharmaceuticals, Inc. Responds to Advisory Committee Recommendation for Further Study of Tedisamil to Treat Atrial Fibrillation
6. XTL Biopharmaceuticals Presents Data Regarding its Hepatitis C Virus Small Molecule Program at Hep Dart 2007 - an International Scientific Conference on Viral Hepatitis
7. Celator(R) Pharmaceuticals Reports CPX-351 Shows Anti-Cancer Activity in Leukemia Patients
8. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
9. Access Pharmaceuticals Demonstrates Ability to Significantly Reduce Glucose Levels in Pre-clinical Testing of Cobalamin(TM) Oral Insulin
10. Vion Pharmaceuticals To Present Preliminary Data on its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) at the American Society of Hematology Meeting
11. Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine(R) (VNP40101M) in Combination with Stem Cell Transplantation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... , Aug. 28, 2014 /PRNewswire-iReach/ -- Gateway Analytical ... the 9 th Annual Global Pharma Manufacturing ... September 8-9 th . The Global Pharma Manufacturing ... in small molecule and biologic pharmaceutical manufacturing. The ... that today,s manufacturers face, such as the increasing ...
(Date:8/28/2014)... , Aug. 28, 2014 /PRNewswire/ ... market research report is available in ... Therapeutics in Asia-Pacific Markets to 2020 ... Unmet Need in Newly Diagnosed and ... http://www.reportlinker.com/p02343492/Glioblastoma-Multiforme-Therapeutics-in-Asia-Pacific-Markets-to-2020---Novel-Therapeutic-Approaches-Target-High-Unmet-Need-in-Newly-Diagnosed-and-Recurrent-GBM.html Glioblastoma ...
(Date:8/28/2014)... MEETING, Pa. , Aug. 28, 2014 /PRNewswire-USNewswire/ ... community, patients, and media, both for the promise ... patient safety. The quick deployment of surgical robots ... technology are prompting facilities to evaluate their robotic ... the entire surgical team.    ECRI ...
Breaking Medicine Technology:Gateway Analytical to Promote Particulate Identification Services at the 9th Annual Global Pharma Manufacturing Summit 2Gateway Analytical to Promote Particulate Identification Services at the 9th Annual Global Pharma Manufacturing Summit 3Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 2Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 3Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 4Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 5Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 6Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 7Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 8Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 9Surgical Robot Risk and Safety: ECRI Institute and Hartford Hospital Launch New Education Series 2Surgical Robot Risk and Safety: ECRI Institute and Hartford Hospital Launch New Education Series 3Surgical Robot Risk and Safety: ECRI Institute and Hartford Hospital Launch New Education Series 4Surgical Robot Risk and Safety: ECRI Institute and Hartford Hospital Launch New Education Series 5
... ANAHEIM, Calif., Feb. 7, 2011 UBM TechInsights ... the smartphone juggernaut will impact revenues, design strategies, and ... same way it has for many consumer products including ... "The question for traditional medical device companies is ...
... Feb. 7, 2011 Today the U.S. Food and Drug ... conduct postmarket surveillance studies to determine the length of time ... or other reasons. (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ) ... the temporal bone in the skull. A person may have ...
Cached Medicine Technology:UBM TechInsights Issues Warning to Medical Devices Industry About Possible Obsolescence as Reliance on Smartphones Increases 2UBM TechInsights Issues Warning to Medical Devices Industry About Possible Obsolescence as Reliance on Smartphones Increases 3UBM TechInsights Issues Warning to Medical Devices Industry About Possible Obsolescence as Reliance on Smartphones Increases 4FDA Orders Postmarket Surveillance of Certain TMJ Implants 2FDA Orders Postmarket Surveillance of Certain TMJ Implants 3
(Date:8/28/2014)... 2014 Testimony began this week ... transvaginal mesh lawsuit ( http://www.transvaginalmeshlawsuithelp.com/ )involving a ... reports. Court documents pending in the U.S. District ... the case was filed on behalf of a ... allegedly due to vaginal mesh complications associated with ...
(Date:8/28/2014)... The Governor of Yucatán, Rolando Zapata Bello, presented the ... this event is organized by the Microcredit Summit Campaign ... National Microenterprise Financing Program ( PRONAFIM ) and will ... the Convention Center Yucatan Siglo XXI in the city ... Yucatan to host the 17th Microcredit Summit logistically but ...
(Date:8/28/2014)... 2014 Kirklyn Smith, an office manager for ... a new world’s record by walking 5,000 miles in a ... constantly amazed by the thousands of individual stories of TrekDesk ... to stand out more than the others. , Kirklyn has ... count which tallies a range of 54,823 steps (presumably on ...
(Date:8/28/2014)... 2014 Bank lending to the private sector ... by 0.13% in real terms, and continuing to fall behind ... by UHY, the international accountancy network. , UHY warns that ... particular, the credit crunch lingers on. , UHY says in ... year have been wiped out by inflation. Over the four ...
(Date:8/28/2014)... 2014 (HealthDay News) -- Lack of sleep not only puts ... at increased risk for obesity, researchers warn. The study ... they were aged 16 and 21. Nearly one-fifth of them ... they were age 16, and this group was 20 percent ... who got more than eight hours of sleep per night ...
Breaking Medicine News(10 mins):Health News:Transvaginal Mesh Lawsuit News: Testimony Begins in Second Federal Ethicon Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuit News: Testimony Begins in Second Federal Ethicon Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Transvaginal Mesh Lawsuit News: Testimony Begins in Second Federal Ethicon Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Governor of the State of Yucatan presents the 17th Microcredit Summit 2Health News:Governor of the State of Yucatan presents the 17th Microcredit Summit 3Health News:There are many reasons why Americans' exercise levels have declined - Meet an executive that refuses to sit still with his TrekDesk Treadmill Desk even in a sedentary job 2Health News:UHY Study Shows Bank Lending In USA Falling Behind G7 Peers 2Health News:UHY Study Shows Bank Lending In USA Falling Behind G7 Peers 3Health News:UHY Study Shows Bank Lending In USA Falling Behind G7 Peers 4Health News:UHY Study Shows Bank Lending In USA Falling Behind G7 Peers 5Health News:UHY Study Shows Bank Lending In USA Falling Behind G7 Peers 6Health News:UHY Study Shows Bank Lending In USA Falling Behind G7 Peers 7Health News:Less Sleep in Teen Years Tied to More Pounds at 21 2
... German . , Scientists at the University ... haemo-globin. Haemoglobin transports oxygen in the red blood corpuscles. ... haemoglobin type appears optically to be transporting little oxygen. ... similar picture to patients suffering from an inherited cardiac ...
... First RTLS Application Using Rich Internet Applications Delivers Intuitive, Web-based ... ... Workflow, SARATOGA, California, March ... Systems (RTLS), today introduced,Ekahau Vision, a web-based visual interface that enables ...
... March 17 Bristol-Myers Squibb,Company (NYSE: BMY ... 28th Annual,Health Care Conference today. Brian Daniels, M.D., ... presentation about the company at,1:45 p.m. ET today., ... Lehman Brothers Global,Healthcare Conference on Wednesday, March 19, ...
... Children with Allergies Less Productive Than Peers, Parents Reported ... largest survey of,its kind suggested there,s a silent epidemic ... and not getting the treatment,they need, according to the ... most comprehensive national survey of parents of children,under the ...
... able to detect early stages of colon cancer without a ... Stanford University School of Medicine. , This imaging technology is ... body in real time, said Christopher Contag, PhD, associate professor ... the study. Contag said he hoped it might be one ...
... vascular proliferation that is hallmark of eye disease ... pinpointed a biological pathway that may block the blood ... in the United States. , Though still preliminary, the ... for such ophthalmic diseases as age-related macular degeneration (AMD) ...
Cached Medicine News:Health News:Bonn scientists discover new hemoglobin type 2Health News:Ekahau Offers Clear Visibility Into Real-Time Location Tracking With Ekahau Vision 2Health News:Ekahau Offers Clear Visibility Into Real-Time Location Tracking With Ekahau Vision 3Health News:Landmark 'Pediatric Allergies in America' Survey Uncovered Negative Impact of Allergy Symptoms on Children 2Health News:Landmark 'Pediatric Allergies in America' Survey Uncovered Negative Impact of Allergy Symptoms on Children 3Health News:Landmark 'Pediatric Allergies in America' Survey Uncovered Negative Impact of Allergy Symptoms on Children 4Health News:Landmark 'Pediatric Allergies in America' Survey Uncovered Negative Impact of Allergy Symptoms on Children 5Health News:Cancer detected earlier, faster, with new medical imaging, Stanford study finds 2Health News:Cancer detected earlier, faster, with new medical imaging, Stanford study finds 3Health News:Study Finds Potential Cause of Age-Related Macular Degeneration 2Health News:Study Finds Potential Cause of Age-Related Macular Degeneration 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: